. 2021 Apr 28;12:659943. doi: 10.3389/fimmu.2021.659943

Table 1.

Phospholipid fatty acid composition of PBMC in Mtb-infected C3HeB/FeJ mice receiving EPA/DHA or ibuprofen adjunct treatment at different time points^#.

4 days post-treatment
Fatty acids	Rifafour	Rifafour + EPA/DHA	Rifafour + ibuprofen	untreated control	P- value
20:5n-3 (EPA)	0.40 ± 0.02^b	0.60 ± 0.02^a	0.35 ± 0.01^b	0.41 ± 0.02^b	<0.001
22:6n-3 (DHA)	11.38 ± 0.32^b	11.54 ± 0.19^b	12.00 ± 0.20^a	12.67 ± 0.21^a,b	0.007
Total n-3 LCPUFA	12.56 ± 0.32^b	12.99 ± 0.17^b	13.12 ± 0.19^a,b	14.05 ± 0.22^a	0.003
20:4n-6 (AA)	17.72 ± 0.37^b	18.38 ± 0.38^a,b	19.31 ± 0.26^a	17.83 ± 0.06^b	0.006
22:5n-6 (osbond)	0.93 ± 0.60	0.89 ± 0.04	0.92 ± 0.03	1.03 ± 0.02	0.19
Total n-6 LCPUFA	22.22 ± 0.50^b	23.22 ± 0.46^a,b	23.82 ± 0.27^a	22.83 ± 0.16^a,b	0.052
Total n-6/n-3 LCPUFA ratio	1.77 ± 0.05^a	1.79 ± 0.03^a	1.82 ± 0.03^a	1.63 ± 0.02^b	0.009
14 days post-treatment
	RH	RH + EPA/DHA	RH + ibuprofen	untreated control	P- value
20:5n-3 (EPA)	0.32 ± 0.0^b	0.74 ± 0.08^a	0.33 ± 0.00^b	0.35 ± 0.00^b	<0.001
22:6n-3 (DHA)	11.87 ± 0.12	12.19 ± 0.37	12.50 ± 0.13	12.26 ± 0.21	0.23
Total n-3 LCPUFA	13.12 ± 0.11^b	14.12 ± 0.38^a	13.90 ± 0.19^a,b	13.76 ± 0.24^a,b	0.039
20:4n-6 (AA)	18.26 ± 0.13^a	17.24 ± 0.24^b	18.83 ± 0.13^a	18.40 ± 0.08^a	<0.001
22:5n-6 (Osbond)	1.18 ± 0.03^a,b	1.07 ± 0.03^b	1.24 ± 0.03^a	1.27 ± 0.04^a	0.003
Total n-6 LCPUFA	23.69 ± 0.15^b	22.51 ± 0.22^c	24.56 ± 0.17^a	23.99 ± 0.16^a,b	<0.001
Total n-6/n-3LCPUFA ratio	1.81 ± 0.01^a	1.60 ± 0.05^b	1.77 ± 0.02^a	1.75 ± 0.02^a	0.001

^#Values are reported as mean ± SEM percentage of total fatty acids from one experiment shown as representative of two independent experiments (n = 6 per group). Means in a row without common superscript letters differ significantly, P < 0.05. One-way ANOVA, with Tukey post hoc test was used to test effects between groups. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LCPUFA, long-chain polyunsaturated fatty acids; N, total number of mice used in experiment; PBMC, peripheral blood mononuclear cell; Rifafour, rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275 mg; RH, rifampicin and isoniazid.